Auritz

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Auritz

What is Auritz? (Foundational Identity)

Property Description
Active ingredient Rosuvastatin calcium
Form Film-coated tablets
Pharmacological class Statin / HMG-CoA reductase inhibitor
Common use Regulation of blood lipid levels
Origin Synthetic compound

Auritz is a synthetic single-component pharmaceutical preparation for oral administration, formally classified as an HMG-CoA reductase inhibitor and broadly known as a statin. Its chemical identity is defined by its active substance, Rosuvastatin calcium. The drug is supplied in the form of film-coated tablets. Rosuvastatin is a high-efficacy member of the statin class, distinguishing it from older antihyperlipidemic agents.


What Type of Medicine is Auritz? (Identity and Classification)

This medicine belongs to the class of statins, which are prescription-only agents used to manage high levels of lipids in the blood. Rosuvastatin's classification as an HMG-CoA reductase inhibitor describes its mechanism of action: it competitively blocks the enzyme in the liver that synthesizes cholesterol. As an antihyperlipidemic agent, its primary therapeutic objective is the regulation of plasma lipid concentrations. Rosuvastatin has a potent and sustained ability to lower cholesterol. This functional classification places it as a foundational medicine in cardiovascular prophylactic strategies.


What is Rosuvastatin and How Does it Help? (Composition and General Purpose)

The fundamental purpose of Auritz is to achieve a substantial and sustained reduction in harmful cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), which is critical for dyslipidemia management. By inhibiting the liver's natural production of cholesterol, Rosuvastatin prompts the liver to actively clear existing LDL-C from the bloodstream. This action is utilized for individuals with primary hyperlipoproteinemia to assist in the management of the lipid profile. This physiological action serves to regulate the body's lipid balance, thereby helping to reduce the overall risk factors associated with the buildup of fatty deposits in the arteries.

Regulatory References

  1. Rosuvastatin tablets FDA Label
  2. Rosuvastatine ELC Public Assessment Report (PAR)
  3. Rosuvastatin MedlinePlus Drug Information

What side effects are possible with Auritz?

Possible Side Effects and Safety Information

The safety profile of Auritz (rosuvastatin calcium) is officially documented across several System-Organ Classes and is categorized by frequency based on regulatory standards. The most Common adverse reactions listed include headache, dizziness, constipation, nausea, abdominal pain, and myalgia (muscle pain). The incidence of new-onset diabetes mellitus is also officially classified as Common, with frequency related to pre-existing risk factors.


Documented Serious Adverse Reactions

The regulatory labeling highlights specific serious adverse reactions, which are generally categorized as Rare or Very Rare. These include Rhabdomyolysis, a severe muscle disorder, and instances of Hepatitis or Hepatic failure. Other documented serious events are Hypersensitivity reactions such as angioedema (swelling) and severe cutaneous reactions like Stevens-Johnson syndrome.


Safety Considerations by Population and Context

Regulatory documents specify that the risk of muscle-related adverse reactions is higher in certain groups. The official label identifies older adults (aged 65 years and over) and Asian patients as populations with documented increased risk for myopathy. Furthermore, the risk of adverse reactions, particularly myopathy and renal effects, is officially noted as dose-dependent, with a higher reporting rate at the maximum dose. The use of Auritz is restricted in patients with active liver disease or severe renal impairment, as defined in the official regulatory documentation.

Overdose and Emergency Response

The official regulatory profile for an overdose of Auritz (Rosuvastatin calcium) describes potential toxicity primarily affecting the musculoskeletal and hepatic systems. Documented manifestations of excessive exposure include the onset of myopathy (muscle pain or weakness) and severe muscle breakdown known as rhabdomyolysis. This latter condition is a serious complication that can lead to acute renal failure due to myoglobinuria. Overdose may also be confirmed by laboratory abnormalities such as persistently elevated creatine kinase (CK) levels and high levels of hepatic transaminases, indicating liver injury. The regulatory documents note that the risk of these severe outcomes is increased for individuals age 65 years or greater and those with existing renal impairment. Management of an overdose is restricted to symptomatic and supportive treatment, as official labeling confirms that no specific antidote is known and procedures like hemodialysis are not expected to be effective. Due to the potential for these severe, life-threatening events, regulatory guidance mandates that users seek immediate medical attention for any suspected overdose. Furthermore, regulatory instruction requires contacting emergency services or the Poison Control helpline when an overexposure is suspected or confirmed.

Therapeutic Uses of Auritz

What Auritz Treats: Main Uses and Benefits

Auritz is a supportive medication generally focused on providing short-term symptomatic relief across several key areas of discomfort, helping patients cope more steadily with episodes where symptoms become disruptive or overwhelming. The medication may assist with managing symptoms related to systemic imbalance in cases where additional symptomatic support is needed.


Easing Periods of Heightened Symptomatic Discomfort

Auritz is relevant in contexts marked by increased discomfort or tension, such as in conditions characterized by periods of heightened symptoms that involve systemic imbalance. It helps address groups of symptoms that may appear suddenly or intensify over time, offering symptomatic relief that contributes to easing the overall symptom load.

The medication is commonly applied in scenarios where symptoms create noticeable physiological strain and in conditions presenting with systemic or localized discomfort.


Supporting Management of Episodic Symptom Patterns

This medication is commonly used across conditions involving episodic or fluctuating manifestations, and is applied in situations where symptoms form part of acute or recurrent episodes. It may provide temporary assistance in symptom stabilization, helping maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Supports Functional Stability Auritz is applied when symptoms interfere with routine activities, assisting with maintaining functional stability.


Relief for Temporary Functional Strain

Auritz is applied in contexts where additional support for symptom management is appropriate, and is relevant when symptoms create noticeable functional strain. It is commonly used when symptoms intensify and supportive relief is needed, providing relief when symptoms interfere with routine activities.

Regulatory References

  1. U.S. National Library of Medicine (NIH)

Eligibility and Restrictions for Use

Eligibility Profile: Official Regulatory Constraints

Regulatory agencies define eligibility for Auritz (Rosuvastatin calcium) based on absolute contraindications and specific population restrictions related to age and pre-existing medical conditions.


Contraindications (Must NOT Use)

Auritz is officially contraindicated and must not be used by the following groups:

  • Patients with Active Liver Disease, including those with unexplained, persistent elevations in hepatic transaminases.
  • Pregnant Women or Women of Childbearing Potential not using reliable contraception.
  • Breastfeeding Women (Lactation).
  • Patients with a known Hypersensitivity to rosuvastatin or any product components.
  • Patients with Severe Renal Impairment (creatinine clearance <30 mL/min).
  • Patients with Myopathy or those taking concomitant Cyclosporine.

Age and Conditional Use Restrictions

  • Adults are the standard population for use.
  • Pediatric Use: The medicine is approved for specific familial hypercholesterolemia conditions in children starting at ages 7 or 8 years, depending on the disorder. Use is Not Recommended in children younger than 6 years, as safety and efficacy have not been established in that group.
  • High Dose Restriction: The 40 mg dose is contraindicated in patients with factors predisposing to myopathy, such as moderate renal impairment or age ge 65 years.
  • Special Considerations: For patients ge 70 years old or those of Asian ancestry, regulatory labeling suggests a lower starting dose should be considered.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Auritz (Rosuvastatin) identifies specific patterns of interaction based on pharmacokinetics and pharmacodynamics. The primary concern is increased Rosuvastatin exposure when co-administered with certain medications, typically mediated by the inhibition of drug transporters like OATP1B1 and BCRP.

Documented Pharmacokinetic and Pharmacodynamic Interactions

Interacting Substance/Class Official Interaction Outcome
Cyclosporine, Gemfibrozil, Protease Inhibitors Significantly increased plasma concentration (exposure) of Rosuvastatin.
Fibrates, High-dose Niacin (≥ 1 g/day) Increased risk of myopathy (muscle damage) and rhabdomyolysis (pharmacodynamic effect).
Coumarin Anticoagulants (e.g., Warfarin) Prolongation of the International Normalized Ratio (INR), requiring close monitoring.
Aluminum and Magnesium Antacids Decreased Rosuvastatin plasma concentration, which is resolved by timing separation.

Specific Regulatory Restrictions and Considerations

Interaction with antacids requires a mandatory timing rule: Auritz must be administered at least 2 hours after the antacid preparation. Furthermore, specific population notes are documented: Asian patients show a two-fold increase in Rosuvastatin median plasma exposure, and patients with certain genetic polymorphisms exhibit higher drug levels. Substantial consumption of alcohol may increase the documented risk of liver-related adverse reactions.

Mechanism of Action

The action of Auritz (Rosuvastatin) is highly targeted to the primary molecular pathway responsible for the body's internal cholesterol production, initiating a precise mechanistic cascade that modulates the systemic parameters of lipid concentration.


Molecular Suppression of Cholesterol Production

The drug engages in competitive inhibition of the HMG-CoA Reductase enzyme, which is the rate-limiting step in the liver's mevalonate pathway. This blocks the hepatocyte's de novo cholesterol synthesis, creating a crucial cellular deficit. This suppression of the internal production mechanism is the foundational molecular event that initiates the subsequent mechanisms.


Receptor-Mediated Plasma Lipid Clearance

The reduced intracellular cholesterol level triggers a compensatory upregulation of LDL receptors on the liver cell surface. These receptors rapidly bind to circulating Low-Density Lipoprotein Cholesterol (LDL-C) particles, increasing the rate of their removal from the bloodstream. The resulting plasma clearance is the main physiological mechanism that results in the reduction in plasma LDL-C concentrations, influencing the systemic feedback mechanisms governing lipid homeostasis.


Cholesterol-Independent Vascular Modulation

Beyond lipid reduction, the mechanism involves pleiotropic effects that modulate endothelial function by influencing processes within the blood vessel lining. This includes effects related to endothelial function and reducing circulating markers of systemic inflammation. This additional mechanistic domain contributes to the non-lipid-related modulation of cardiovascular system parameters.

Dosage and Administration Information

Auritz (rosuvastatin) is an oral medication that must be taken exactly as prescribed. The drug should be used in conjunction with a cholesterol-lowering diet.

Administration Guidelines

Attribute Instruction
Route of Administration The tablets must be taken orally.
Dose Frequency Take once daily, administered as a single dose.
Timing & Food Can be taken at any time of day and administered with or without food.
Tablet Integrity The tablet must be swallowed whole; it should not be crushed, dissolved, or chewed.

Dosing and Population-Specific Rules

Dosage ranges from 5 mg to 40 mg once daily. The usual starting dose is 10 mg or 20 mg. The 40 mg dose is reserved for patients who have not achieved their treatment goal on the 20 mg dose. Adjustments to the dose may be made by a healthcare professional as early as four weeks after starting therapy.

Starting dose adjustments are required for specific patient populations:

  • Asian Patients: A starting dose of 5 mg once daily should be considered.
  • Severe Renal Impairment: The recommended starting dose is 5 mg once daily, and the dose should not exceed 10 mg once daily.
  • Missed Dose: If a dose is missed, do not take an extra dose. Treatment should resume with the next regularly scheduled dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Auritz

This section provides an overview of the official clinical research and study designs used in the evaluation of Auritz (Rosuvastatin calcium), relying exclusively on regulatory and peer-reviewed scientific sources. The text summarizes what the research examined and reported, without offering any clinical advice or interpretation.


Evidence for the Management of Dyslipidemia

The foundational research for Auritz was evaluated in numerous controlled clinical trials, including short-term studies comparing it against a placebo or other active comparator agents. Research examined the medicine's influence on various outcomes related to systemic or functional imbalance in lipid levels. The primary focus of these trials was monitoring changes in laboratory values, chiefly the measured change in LDL cholesterol (LDL-C). Findings describe patterns observed in the studies where measured changes in these lipid biomarkers occurred over the short-term treatment intervals.

Long-term effects are not fully established based on these specific, short-duration efficacy trials. The trials were focused on surrogate endpoints (biomarker shifts) and do not provide direct evidence on the frequency of clinical events (e.g., heart attack or stroke) over many years.


Evidence for the Primary Prevention of Major Cardiovascular Events

Research examined Auritz in the context of the primary prevention of major cardiovascular events. This research involved large, placebo-controlled Randomized Controlled Trials (RCTs) conducted across many international sites. These studies were evaluated in adults who did not yet have established heart disease but who had been identified by their healthcare providers as having multiple risk factors for heart conditions, including elevated inflammatory markers like high-sensitivity C-reactive protein (hsCRP).

The primary clinical outcomes studies examined were related to major cardiovascular events, such as the occurrence of a first nonfatal heart attack or nonfatal stroke. One key research limitation frames the initial analysis: some of the most definitive trials were stopped early, which means the final published data reflect a shorter median follow-up duration than originally planned.

Key Studies & References

  1. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)
  2. Public Assessment Report Scientific discussion Rosuvastatine Denk (EMA/National Authority Document)

Frequently Asked Questions (FAQ)

Common questions about Auritz (FAQ)

Q: Is Auritz similar to [Competitor Drug Name]? What's the general difference?

Auritz's active ingredient, rosuvastatin, belongs to the statin class of medicines. Like others in this class, it works by blocking the enzyme in the liver that produces cholesterol. Regulatory analysis describes rosuvastatin as a potent inhibitor of this enzyme compared to other agents in the class.

Q: Can women who are pregnant or breastfeeding use Auritz?

Official documentation strictly states that Auritz is contraindicated, meaning it must not be used, during pregnancy or while breastfeeding. This restriction is based on the potential for serious harm to the developing fetus or the nursing infant, as described in the official product information.

Q: Can I take ibuprofen or Tylenol while using Auritz?

Specific warnings for taking Auritz with common over-the-counter pain relievers like acetaminophen (Tylenol) or ibuprofen have not been established in official regulatory documents. Since some medicines can affect liver health, which is a consideration for statin users, a discussion with a healthcare professional regarding all medications is required.

Q: What if I start feeling better; should I still finish the prescribed course?

Auritz is prescribed for long-term management of high cholesterol to reduce future health risks, not to treat symptoms that can be felt. Official guidance emphasizes that cholesterol levels cannot be personally sensed, so the medicine is intended to be continued exactly as directed. Stopping the medicine may reverse the beneficial cholesterol-lowering effects.

Q: How quickly can someone typically expect Auritz to start working?

While the medicine begins acting on the cholesterol enzyme immediately after the first dose, the measurable cholesterol-lowering effect takes time to become fully established. Studies show that the cholesterol-lowering results generally approach their maximum level within two to four weeks of consistent treatment.

Q: Can Auritz cause a change in mood or anxiety levels?

Official drug information identifies depression as an adverse reaction that has been reported for rosuvastatin. Additionally, official records have noted non-serious cognitive effects such as confusion and memory loss across the statin class, which may indirectly affect mood.

Q: What happens if I accidentally miss a day of taking Auritz?

The official instruction for a missed dose is to skip that dose entirely and simply take the next dose at its regularly scheduled time. This directive is given to prevent the user from accidentally taking two doses too close together.

Q: Is it possible to develop a dependency on Auritz?

No, Auritz (rosuvastatin) is not classified as an addictive or controlled substance by regulatory bodies. Official sources show there is no evidence that taking this medicine leads to dependency or withdrawal symptoms if the treatment is stopped.

Q: Are there any long-term effects of taking Auritz for an extended time?

Official research supports the use of statins for the long-term management of cardiovascular risk factors, with ongoing regulatory monitoring. While very serious long-term adverse events, such as severe muscle problems or liver damage, are possible, they are officially classified as rare side effects.

Q: Can Auritz affect sleep patterns?

Official drug information lists difficulty falling asleep or staying asleep (insomnia) as a possible adverse reaction of rosuvastatin. Other less common side effects reported have included nightmares.

Q: Do coffee or caffeine products interact with Auritz?

Official drug interaction databases indicate that no clinically significant interaction is documented between Auritz and moderate consumption of coffee or caffeine. This suggests that the process the body uses to break down rosuvastatin is not significantly affected by caffeine.

Q: Is Auritz safe for older adults or seniors?

Auritz is approved for use in individuals aged 65 and older. Official labeling indicates that older adults may have an increased risk of muscle-related adverse reactions (myopathy) and that a healthcare professional may recommend a lower starting dose.

Q: Why is Auritz sometimes prescribed at a lower starting amount?

Official guidelines recommend considering a lower starting amount for certain populations, such as patients of Asian ancestry and those with severe kidney problems. This is because these groups may naturally have higher levels of the drug in their plasma, which is associated with an increased risk of side effects.

Q: How long does Auritz stay in your system after stopping treatment?

The active ingredient in Auritz, rosuvastatin, has an elimination half-life of approximately 19 hours. This means it takes about 19 hours for the amount of medicine in the body to be reduced by half. The medicine is largely cleared from the system within a few days after stopping therapy.

Q: Can I still consume small amounts of alcohol while taking Auritz?

Official regulatory documents specifically warn that substantial consumption of alcohol may increase the documented risk of liver-related problems. The possibility of liver issues is a documented general concern associated with the use of this type of medicine.

Q: Is Auritz a treatment that works for everyone?

Clinical trials describe the effectiveness of Auritz for its indicated purposes, such as reducing elevated cholesterol levels. No medicine is guaranteed to achieve the intended results for every individual, and the actual effectiveness is evaluated by healthcare professionals based on required monitoring.

Q: Are there any known issues with taking herbal supplements alongside Auritz?

Official interaction databases contain warnings for certain herbal supplements that may affect how statins are broken down by the body, such as St. John's wort. Additionally, supplements like red yeast rice are sometimes advised against as they contain statin-like components.

Q: Does Auritz interact with birth control pills?

Yes, official labeling notes that taking Auritz alongside oral contraceptives may increase the plasma concentration of certain hormones in the birth control pill. Regulatory guidance requires consultation with a healthcare professional regarding the use of birth control when starting or adjusting this medicine.

Q: Does Auritz have a generic version available?

Yes, Auritz, which contains rosuvastatin calcium, is available in a generic form. The regulatory authority has approved multiple generic rosuvastatin products that contain the same active ingredient.

Q: Does Auritz affect your ability to drive or operate machinery?

Official documents describe side effects such as dizziness and headache that may affect concentration or motor skills. These effects indicate that caution regarding personal functioning may be necessary until an individual is aware of how the medicine affects them.

Q: Does Auritz have any interaction warnings with grapefruit?

Official regulatory reviews and pharmacological data indicate that Auritz (rosuvastatin) has no clinically significant interaction with grapefruit or grapefruit juice. This is because this particular statin is metabolized in a way that differs from other members of the class.

Q: What happens if I take too much Auritz by mistake?

Official regulatory documents state there is no specific treatment for an overdose of Auritz. In the event of an overdose, general supportive measures are recommended, along with clinical monitoring of muscle and liver function by a healthcare professional.

Q: Does Auritz require regular blood tests?

Official guidelines recommend testing liver enzymes before starting Auritz therapy. Blood tests may be performed thereafter as clinically indicated, which means they are not routinely required unless there are signs of liver or muscle problems.

Q: Can I take vitamins with Auritz?

General vitamins are not listed as contraindications in official sources. However, certain high-dose vitamins, particularly Niacin (Vitamin B3), are documented as having an interaction that may increase the risk of muscle damage (myopathy) and require discussion with a healthcare professional.

Q: What should I do if a side effect seems serious?

Official patient information outlines that individuals should promptly contact their healthcare provider or seek emergency medical help if they experience symptoms of serious adverse reactions. This includes unexplained muscle pain, fever, signs of liver problems (such as yellowing of the skin), or symptoms of a severe allergic reaction (like swelling).

Q: Are the research studies on Auritz from before or after it was approved?

The foundational clinical trials that established the efficacy and safety of Auritz were conducted before the medicine received regulatory approval. Additional post-marketing studies and ongoing safety surveillance are continuously performed after approval.

Q: Is Auritz used differently for men versus women?

Official pharmacokinetic studies found no differences in the plasma concentrations of rosuvastatin between men and women. This suggests that gender does not affect the typical dosage or use of the medicine.

Q: Is it true that Auritz is a relatively new medicine?

Auritz (rosuvastatin) was first approved in the United States in 2003. While new medications continue to enter the market, rosuvastatin has been an established member of the statin class for over two decades.

How should Auritz be stored and disposed of?

How to Store and Dispose of Auritz?

The official regulatory guidance defines strict environmental conditions for storing Auritz (Rosuvastatin calcium) film-coated tablets to maintain product integrity.

Storage Requirement Official Condition
Temperature Store at controlled room temperature, 68 F to 77 F (20 C to 25 C), and do not freeze.
Container & Protection Keep in the original container, tightly closed, and protect from light and moisture (dry place).
Stability Do not use the tablets after the expiry date stated on the packaging.
Safety Keep this medicine out of the sight and reach of children and pets.

For disposal, do not flush unused or expired Auritz down the toilet or sink. The official instruction is to ask a healthcare professional or pharmacist about the proper method for discarding unused or outdated medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Auritz found in:

A-Z Index: